Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer

被引:0
|
作者
Ji, Bin [1 ]
Li, Wenjia [2 ]
Wang, Wan [2 ]
Min, Kaiyin [1 ]
Yang, Bowen [1 ]
Wan, Qichang [3 ]
Liu, Junzhi [1 ]
Gao, Shi [1 ]
机构
[1] Jilin Univ, Dept Nucl Med, China Japan Union Hosp, Changchun 130033, Peoples R China
[2] Jilin Univ, Dept Breast Surg, China Japan Union Hosp, Changchun 130033, Peoples R China
[3] Guangzhou Med Univ, Affiliated Qingyuan Hosp, Qingyuan Peoples Hosp, Dept Nucl Med, Qingyuan 511500, Peoples R China
关键词
F-18-FAPI PET/CT; F-18-FDG PET/CT; Breast cancer; Systemic staging; Sensitivity;
D O I
10.1016/j.acra.2024.07.058
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: The purpose of this study was to compare the performance of F-18-FAPI PET/CT and F-18-FDG PET/CT in systemic staging of newly diagnosed breast cancer. Methods: Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both F-18-FAPI and F-18-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard. Results: 38 patients were included. The overall upstaging rate was 47.4% for F-18-FAPI PET/CT (18/38) and 34.2% for F-18-FDG PET/CT (13/38). The rate of distant metastases disclosed by F-18-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of F-18-FAPI PET/CT was significantly different from that of F-18-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of F-18-FAPI PET/CT was significantly higher than that of F-18-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)]. Conclusion: F-18-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than F-18-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of F-18-FAPI PET/CT in evaluation of metastatic disease burden. (c) 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 50 条
  • [41] FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
    Hicks, Rodney J.
    Roselt, Peter J.
    Kallur, Kumarswamy G.
    Tothill, Richard W.
    Mileshkin, Linda
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (03) : 296 - 302
  • [42] 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
    Krause, Bernd J.
    Herrmann, Ken
    Wieder, Hinrich
    zum Bueschenfelde, Christian Meyer
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 89S - 96S
  • [43] Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma
    Hogan, Molly P.
    Goldman, Debra A.
    Dashevsky, Brittany
    Riedl, Christopher C.
    Goenen, Mithat
    Osborne, Joseph R.
    Jochelson, Maxine
    Hudis, Clifford
    Morrow, Monica
    Ulaner, Gary A.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) : 1674 - 1680
  • [44] Neurolymphomatosis Diagnosed by 18F-FDG PET-CT
    Salm, Liesbeth P.
    Van der Hiel, Bernies
    Stokkel, Marcel P. M.
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (06) : E261 - E262
  • [45] Limbic Encephalitis Diagnosed With 18F-FDG PET/CT
    Cozar Santiago, Maria Del Puig
    Sanchez Jurado, Raul
    Sanz Llorens, Rut
    Aguilar Barrios, Jose Enrique
    Ferrer Rebolleda, Jose
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (02) : E101 - E103
  • [46] Intestinal amyloidosis diagnosed by 18F-FDG PET/CT
    Casillas Sagrado, E.
    Pena Pardo, F. J.
    Palomo Cousido, S.
    Garcia Vicente, A. M.
    Soriano Castrejon, A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 39 (02): : 98 - 99
  • [47] Correlation of Breast Cancer Subgroups and Axillary Metastases with 18F-FDG PET/CT and the Contribution of 18F-FDG PET/CT in the Management of the Axilla
    Ozer, Nazmi
    Sahin, Abdullah
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (02): : 150 - 155
  • [48] Comparison of 18F-FDG PET/CT and 18F-FDG PET/MRI in Detection of Liver Lesions in Hepatocellular Carcinoma for Staging and Restaging
    Demir, B.
    Soydal, C.
    Dursun, E.
    Araz, M.
    Oz, D. Kuru
    Kucuk, N. O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S71 - S71
  • [49] 18F-FDG PET/CT in Bladder Cancer
    Tagliabue, Luca
    Russo, Giovanna
    Lucignani, Giovanni
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (12) : E522 - E524
  • [50] 18F-FDG PET/CT in ovarian cancer
    Gregianin, M.
    Dalla Palma, M.
    Evangelista, L.
    Cervino, A. R.
    Saladini, G.
    Borgato, L.
    Nicoletto, M. O.
    Zagonel, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S120 - S120